136 related articles for article (PubMed ID: 12397554)
21. Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.
Teh LK; Hamzah S; Hashim H; Bannur Z; Zakaria ZA; Hasbullani Z; Shia JK; Fijeraid H; Md Nor A; Zailani M; Ramasamy P; Ngow H; Sood S; Salleh MZ
Ther Drug Monit; 2013 Oct; 35(5):624-30. PubMed ID: 23942539
[TBL] [Abstract][Full Text] [Related]
22. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
23. [Pro or con the phenotyping/genotyping of patients treated by 5-Fluorouracil to prevent adverse drug reactions?].
Coriat R; Chaussade S
Therapie; 2007; 62(2):105-9. PubMed ID: 17582310
[TBL] [Abstract][Full Text] [Related]
24. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
van Kuilenburg AB; Muller EW; Haasjes J; Meinsma R; Zoetekouw L; Waterham HR; Baas F; Richel DJ; van Gennip AH
Clin Cancer Res; 2001 May; 7(5):1149-53. PubMed ID: 11350878
[TBL] [Abstract][Full Text] [Related]
25. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
Hooiveld EA; van Kuilenburg AB; Haanen JB; Westermann AM
Ned Tijdschr Geneeskd; 2004 Mar; 148(13):626-8. PubMed ID: 15083629
[TBL] [Abstract][Full Text] [Related]
26. Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea.
Meinsma R; Fernandez-Salguero P; Van Kuilenburg AB; Van Gennip AH; Gonzalez FJ
DNA Cell Biol; 1995 Jan; 14(1):1-6. PubMed ID: 7832988
[TBL] [Abstract][Full Text] [Related]
27. 5-Fluorouracil pharmacogenomics: still rocking after all these years?
Scartozzi M; Maccaroni E; Giampieri R; Pistelli M; Bittoni A; Del Prete M; Berardi R; Cascinu S
Pharmacogenomics; 2011 Feb; 12(2):251-65. PubMed ID: 21332317
[TBL] [Abstract][Full Text] [Related]
28. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.
Wei X; McLeod HL; McMurrough J; Gonzalez FJ; Fernandez-Salguero P
J Clin Invest; 1996 Aug; 98(3):610-5. PubMed ID: 8698850
[TBL] [Abstract][Full Text] [Related]
29. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity.
Van Kuilenburg AB; Vreken P; Beex LV; Meinsma R; Van Lenthe H; De Abreu RA; Van Gennip AH
Adv Exp Med Biol; 1998; 431():293-8. PubMed ID: 9598078
[No Abstract] [Full Text] [Related]
30. Is fluorouracil-induced severe toxicity in DPYD*2A individuals related to sex or to treatment regimen?
Deenen MJ; Beijnen JH; Schellens JH
J Clin Oncol; 2008 Oct; 26(30):4997-8; author reply 4998-9. PubMed ID: 18809598
[No Abstract] [Full Text] [Related]
31. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
32. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?
Ciccolini J; Gross E; Dahan L; Lacarelle B; Mercier C
Clin Colorectal Cancer; 2010 Oct; 9(4):224-8. PubMed ID: 20920994
[TBL] [Abstract][Full Text] [Related]
33. Impact of dihydropyrimidine dehydrogenase on 5-fluorouracil treatment in cancer patients.
Schneider HB; Becker H
Eur J Med Res; 2003 May; 8(5):226-8. PubMed ID: 12844478
[TBL] [Abstract][Full Text] [Related]
34. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
Gross E; Ullrich T; Seck K; Mueller V; de Wit M; von Schilling C; Meindl A; Schmitt M; Kiechle M
Hum Mutat; 2003 Dec; 22(6):498. PubMed ID: 14635116
[TBL] [Abstract][Full Text] [Related]
35. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.
Johnson MR; Hageboutros A; Wang K; High L; Smith JB; Diasio RB
Clin Cancer Res; 1999 Aug; 5(8):2006-11. PubMed ID: 10473079
[TBL] [Abstract][Full Text] [Related]
36. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients.
Van Kuilenburg AB; van Lenthe H; Blom MJ; Mul EP; Van Gennip AH
Br J Cancer; 1999 Feb; 79(3-4):620-6. PubMed ID: 10027339
[TBL] [Abstract][Full Text] [Related]
37. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.
Boisdron-Celle M; Remaud G; Traore S; Poirier AL; Gamelin L; Morel A; Gamelin E
Cancer Lett; 2007 May; 249(2):271-82. PubMed ID: 17064846
[TBL] [Abstract][Full Text] [Related]
38. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil.
Johnson MR; Diasio RB
Adv Enzyme Regul; 2001; 41():151-7. PubMed ID: 11384742
[No Abstract] [Full Text] [Related]
39. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.
Thomas F; Hennebelle I; Delmas C; Lochon I; Dhelens C; Garnier Tixidre C; Bonadona A; Penel N; Goncalves A; Delord JP; Toulas C; Chatelut E
Clin Pharmacol Ther; 2016 Feb; 99(2):235-42. PubMed ID: 26265035
[TBL] [Abstract][Full Text] [Related]
40. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.
Milano G; Etienne MC; Pierrefite V; Barberi-Heyob M; Deporte-Fety R; Renée N
Br J Cancer; 1999 Feb; 79(3-4):627-30. PubMed ID: 10027340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
